Further analysis suggests positive Phase III result for Diurnal

Diurnal (AIM: DNL) has provided an update on its Alkindi (hydrocortisone) and Chronocort (hydrocortisone) program, stating that a further analysis of data shows a more promising result than it had first thought.

The original analysis found that Chronocort had not met the primary endpoint in its European Phase III trial for the treatment of congenital adrenal hyperplasia (CAH).

The firm now says a number of patients on the safety extension trial have been treated for at least a year, and show “sustained benefit from extended Chronocort treatment, consistent with feedback from the study investigators.”